An emerging application of viruses involves engineering them to treat diseases using a number of approaches. Broadly defined under the “Virotherapy” umbrella, these include viral vectors used for gene therapy, oncolytic viruses and viral immunotherapy.
A significant challenge, as it is for any virus-based technology, is gaining a clear picture of the quality of a sample at any given point: From early research and development through manufacturing and product release. Of prime concern is the quantification of viruses, which in the past, has relied on slow, labor-intensive, subjective methods such as plaque titer assay and electron microscopy. However, the diversity of new viral technologies now being used as the basis for innovative drugs and vaccines requires improved analytical systems.
- Explore how new virotherapies are moving towards reprogramming viruses
- Assess the true impact of delays in virus quantification
- Understand how real-time enumeration of viruses can significantly enhance the pace of Virotherapy product development.
You can meet ViroCyt, who produced this whitepaper, at the World Vaccine Congress 2015 in Washington D.C. on April 7-9 to talk about how you could apply these kinds of technology to your vaccine development.